<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Intellia Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/intellia-therapeutics-inc</link>
<description>Latest news and press releases for Intellia Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/intellia-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a3db78dffbe2df10a64f.webp</url>
<title>Intellia Therapeutics Inc</title>
<link>https://6ix.com/company/intellia-therapeutics-inc</link>
</image>
<item>
<title>Intellia Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-announces-proposed-public-offering-of-common-stock</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-announces-proposed-public-offering-of-common-stock</guid>
<pubDate>Mon, 27 Apr 2026 20:01:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has commenced an underwritten public offering of $150 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offere</description>
</item>
<item>
<title>Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-reports-positive-phase-3-results-in-hereditary-angioedema-marking-a-global-first-for-in-vivo-gene-editing</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-reports-positive-phase-3-results-in-hereditary-angioedema-marking-a-global-first-for-in-vivo-gene-editing</guid>
<pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
<description>Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from both attacks and ongoing therapy for six-month efficacy evaluation period, demonstrating its potential to be the first and only one-time HAE treatmentRolling biologics license application (BLA) submission initiated with the U.S. Food and Drug Administration (FDA); anticipate U.S. launch in the first hal</description>
</item>
<item>
<title>Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-lonvoguran-ziclumeran-lonvo-z-as-a-one-time-treatment-for-hereditary-angioedema</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-initiates-rolling-submission-of-biologics-license-application-to-fda-for-lonvoguran-ziclumeran-lonvo-z-as-a-one-time-treatment-for-hereditary-angioedema</guid>
<pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
<description>Expect to complete BLA submission in second half of 2026; anticipate launch in first half of 2027, if approvedCAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced it has initiated a rolling submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of</description>
</item>
<item>
<title>Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-to-report-topline-data-from-global-phase-3-haelo-clinical-trial-of-lonvoguran-ziclumeran-in-hereditary-angioedema-on-april-27-2026</guid>
<pubDate>Fri, 24 Apr 2026 20:05:00 GMT</pubDate>
<description>World’s first Phase 3 readout for an in vivo CRISPR gene editing candidateCompany to host webcast to discuss data at 8:00 a.m. ET on April 27, 2026 CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the company will report topline clinical data from its global Phase 3 HAELO clinical trial of lonvoguran zi</description>
</item>
<item>
<title>Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-presents-longer-term-clinical-data-for-lonvoguran-ziclumeran-lonvo-z-hereditary-angioedema-hae-patient-focused-research-at-aaaai-2026</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-presents-longer-term-clinical-data-for-lonvoguran-ziclumeran-lonvo-z-hereditary-angioedema-hae-patient-focused-research-at-aaaai-2026</guid>
<pubDate>Tue, 03 Mar 2026 12:30:00 GMT</pubDate>
<description>Presentations include three-year follow-up data from patients receiving a one-time 50 milligram (mg) dose of lonvo-z and survey findings highlighting patients’ continued treatment burden and unmet needsCAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced details about its presentation of four posters at the</description>
</item>
<item>
<title>Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-announces-fda-lift-of-clinical-hold-on-magnitude-phase-3-clinical-trial-in-attr-cm</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-announces-fda-lift-of-clinical-hold-on-magnitude-phase-3-clinical-trial-in-attr-cm</guid>
<pubDate>Mon, 02 Mar 2026 12:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the U.S. Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug application (IND) for the MAGNITUDE Phase 3 clinical trial of nexiguran ziclumeran (nex-z) for patients with transthyretin amyloidosis with card</description>
</item>
<item>
<title>Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-business-updates</guid>
<pubDate>Thu, 26 Feb 2026 12:30:00 GMT</pubDate>
<description>HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second half of 2026FDA engagement ongoing to resolve clinical hold on MAGNITUDE Phase 3 clinical trial of nex-z in ATTR-CM Ended 2025 with approximately $605 million in cash, cash equivalents and marketable s</description>
</item>
<item>
<title>Intellia Therapeutics to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on</description>
</item>
<item>
<title>Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-to-hold-conference-call-to-discuss-fourth-quarter-and-full-year-2025-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-to-hold-conference-call-to-discuss-fourth-quarter-and-full-year-2025-financial-results-and-business-updates</guid>
<pubDate>Thu, 19 Feb 2026 12:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will host a conference call on February 26, 2026, at 8 a.m. ET to discuss its fourth quarter and full-year 2025 financial results and business updates. To join a webcast of the call, please visit this link. To join the teleconference, U.S. callers should dial</description>
</item>
<item>
<title>Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-announces-fda-lift-clinical-hold-magnitude-2-phase-3-clinical</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-announces-fda-lift-clinical-hold-magnitude-2-phase-3-clinical</guid>
<pubDate>Tue, 27 Jan 2026 05:00:00 GMT</pubDate>
<description>Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM</description>
</item>
<item>
<title>Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-present-44th-annual-123000361</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-present-44th-annual-123000361</guid>
<pubDate>Wed, 07 Jan 2026 12:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the company will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026 at 9:00 a.m. PT. A live webcast will be available on the Events and Presentations page in the Investors & Media section of Intellia’s website, www.</description>
</item>
<item>
<title>Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2026</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2026</guid>
<pubDate>Fri, 02 Jan 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Jan. 02, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on</description>
</item>
<item>
<title>Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-presents-positive-longer-term-phase-1-data-nexiguran-ziclumeran</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-presents-positive-longer-term-phase-1-data-nexiguran-ziclumeran</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease</description>
</item>
<item>
<title>Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-presents-positive-pooled-phase-1-2-data-lonvoguran-ziclumeran</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-presents-positive-pooled-phase-1-2-data-lonvoguran-ziclumeran</guid>
<pubDate>Sat, 08 Nov 2025 05:00:00 GMT</pubDate>
<description>Deep, stable and durable reductions in kallikrein observed Among 32 patients who received a 50 mg dose of lonvo-z as of data cutoff: 31 (97%) were attack-free</description>
</item>
<item>
<title>Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-announces-third-quarter-2025-financial-results-and-recent</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-announces-third-quarter-2025-financial-results-and-recent</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 clinical data of nex-z for ATTR-CM on</description>
</item>
<item>
<title>Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-provides-update-magnitude-clinical-trials-nexiguran-ziclumeran</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-provides-update-magnitude-clinical-trials-nexiguran-ziclumeran</guid>
<pubDate>Mon, 27 Oct 2025 04:00:00 GMT</pubDate>
<description>Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage</description>
</item>
<item>
<title>Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-announces-positive-longer-term-phase-1-data-nexiguran</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-announces-positive-longer-term-phase-1-data-nexiguran</guid>
<pubDate>Thu, 25 Sep 2025 04:00:00 GMT</pubDate>
<description>One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization</description>
</item>
<item>
<title>Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-present-longer-term-data-ongoing-phase-1-clinical-trial</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-present-longer-term-data-ongoing-phase-1-clinical-trial</guid>
<pubDate>Mon, 22 Sep 2025 04:00:00 GMT</pubDate>
<description>Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 highlighting up to three years of</description>
</item>
<item>
<title>Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-completes-enrollment-global-phase-3-haelo-study-lonvoguran</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-completes-enrollment-global-phase-3-haelo-study-lonvoguran</guid>
<pubDate>Thu, 18 Sep 2025 04:00:00 GMT</pubDate>
<description>Completed patient enrollment within nine months with nearly half enrolled from the U.S.Expect to report Phase 3 topline data in the first half of 2026On track</description>
</item>
<item>
<title>Intellia Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Company Progress</title>
<link>https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-announces-second-quarter-2025-financial-results-and-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/intellia-therapeutics-inc/news/intellia-therapeutics-announces-second-quarter-2025-financial-results-and-highlights</guid>
<pubDate>Thu, 07 Aug 2025 04:00:00 GMT</pubDate>
<description>Enrollment in the global Phase 3 MAGNITUDE trial of nexiguran ziclumeran (nex-z) in ATTR with cardiomyopathy (ATTR-CM) continues to track ahead of</description>
</item>
</channel>
</rss>